Xcout IntelLiminatus Pharma, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Liminatus Pharma, Inc. among pharmaceuticals companies — ranked by similarity to what Liminatus Pharma, Inc. actually does, not by market-cap band.
Subscribe to see Liminatus Pharma, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Liminatus Pharma, Inc.
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
Liminatus Pharma, Inc. at a glance
Liminatus Pharma, Inc. is a pharmaceuticals company headquartered in Cerritos, United States. It is publicly listed (LIMN) with a market capitalisation of $5.2M. Xcout tracks 15 named people at Liminatus Pharma, Inc., including Chris Kim (CEO, Chairman & President).
Liminatus Pharma, Inc. leadership
- Chris KimCEO, Chairman & President
- Scott DamChief Financial Officer
- Beom Kyu ChoiChief Technology Officer & Member of Scientific Advisory Board
- Byong Chul YooChief Science Officer & Member of Scientific Advisory Board
- Beom K. ChoiExecutive Officer
- Byong C. YooExecutive Officer
9 more named people on record for Liminatus Pharma, Inc., with roles, board committees and tenure — see the full roster →
Top 12 Liminatus Pharma, Inc. competitors
Ranked by semantic similarity — how close each company is to Liminatus Pharma, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology/Pharmaceuticals
InnocsAI entered into a definitive merger agreement with California-based Liminatus Pharma. Under the terms of this agreement, InnocsAI will merge with and into a newly formed wholly owned Delaware subsidiary of Liminatus.
Biotech, Pharmaceuticals
NeoImmuneTech, Inc. is a company dedicated to expanding the horizon of immuno-oncology (I-O) and infectious diseases. Its headquarters are located in Rockville, Maryland.
Similar pharmaceuticals company
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
Similar pharmaceuticals company
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
Pharmaceuticals, Biotechnology & Life Sciences
Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers. Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer. The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries. Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma. Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.
Similar pharmaceuticals company
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
Similar pharmaceuticals company
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Pharmaceuticals, Biotechnology & Life Sciences
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Similar pharmaceuticals company
Lite Strategy, Inc. is a pharmaceutical company currently in the clinical development phase, primarily dedicated to creating novel treatments for various forms of cancer. Among its key initiatives, the company is advancing ME-344, an intravenously administered small molecule. This therapy is designed to inhibit mitochondrial oxidative phosphorylation and aims to combat specific cancer types, including human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and other solid tumors. In addition to its drug development activities, Lite Strategy also engages in the management of digital asset treasuries. The organization, which was formerly known as MEI Pharma, Inc., is slated to officially adopt the name Lite Strategy, Inc. in September 2025. Established in 2000, the company maintains its headquarters in San Diego, California.
Similar pharmaceuticals company
Ottimo Pharma is an innovative, clinical-stage private biotechnology company co-founded in 2020 by Medicxi and Jonny Finlay. The company is focused on developing pioneering bi-functional medicines and one-of-a-kind PD-1/VEGFR2 dual-paratopic antibodies to extend the lives of cancer patients.
Similar pharmaceuticals company
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
Similar pharmaceuticals company
Lipella Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the creation of novel therapies. The company achieves this by repurposing and optimizing the active ingredients found in established generic drugs, tailoring these reformulations for diverse medical applications. Its lead candidate, LP-10, a tacrolimus formulation, is presently in Phase IIa clinical studies, targeting radiation-induced hemorrhagic cystitis. Additionally, LP-310, another tacrolimus-derived compound, is under development for the management of oral lichen planus. Founded in 2005, the company maintains its headquarters in Pittsburgh, Pennsylvania.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Liminatus Pharma, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Liminatus Pharma, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →